About-cancer/treatment/drugs/eltrombopagolamine/zh

Eltrombopag Olamine

本頁包含有關Eltrombopag olamine的簡要信息，以及一些連結，這些連結指向有關該藥物的用途，研究結果和正在進行的臨床試驗的更多信息。

美國品牌名稱

Promacta

FDA批准

是

該藥物的FDA標籤信息可從DailyMed獲得。

用於癌症

Eltrombopag olamine被批准用於治療：

• 血小板減少症 （低血小板水平）。 它用於成人和1歲或1歲以上的慢性免疫性血小板減少症（ITP）的兒童。 ITP是血小板被免疫系統破壞的疾病。 Eltrombopag olamine用於某些ITP患者，但其他治療未見好轉。

Eltrombopag olamine也正在研究其他疾病和類型的癌症中。

關於Eltrombopag Olamine的更多信息

NCI藥物詞典中的定義-該藥物的詳細科學定義和其他名稱。

MedlinePlus Information on Eltrombopag Olamine - A lay language summary of important information about this drug that may include the following:

• warnings about this drug,

• what this drug is used for and how it is used,

• what you should tell your doctor before using this drug,

• what you should know about this drug before using it,

• other drugs that may interact with this drug, and

• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Clinical Trials Accepting Patients

Find Clinical Trials for Eltrombopag Olamine - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.